title: Genetic background of Lewis negative blood group phenotype and its association with atherosclerotic disease in the NHLBI family heart study.
abstract: OBJECTIVE
  To examine the prevalence of four mutations, T59G, T1067A, T202C and C314T, of the human alpha(1,3/1,4) fucosyltransferase 3 (FUT 3) gene amongst persons with Lewis negative and those with Lewis positive blood group phenotype. An additional objective was to explore the hypothesis that these mutations are associated with coronary heart disease and inflammatory reaction.
  
  
  METHODS
  A population-based cross-sectional study.
  
  
  METHODS
  Analysis of samples and data from the National Heart Lung and Blood Institute Family Heart Study.
  
  
  METHODS
  All Lewis (a-b-) participants (n = 136) and a sample of Lewis positive participants (n = 136) of the Family Heart Study; all were of Caucasian ethnicity.
  
  
  METHODS
  The prevalence of examined mutations by Lewis phenotype.
  
  
  RESULTS
  The examined mutations were common and strongly associated with the Lewis (a-b-) phenotype. Accordingly, 90-95% of Lewis (a-b-) individuals amongst Caucasians can be identified by screening for these four mutations. Exploratory analyses suggested that with the exception of T59G, all examined mutations were positively associated with prevalent coronary heart disease, although not statistically significantly, perhaps due to the small number of prevalent coronary heart disease cases. C-reactive protein tended to be higher amongst persons with a TC or CC genotype at position 202 (3.07 +/- 0.41 vs. 2.08 +/- 0.32 mg L-1, P = 0.06).
  
  
  CONCLUSIONS
  Four specific mutations of fucosyltransferase 3 gene are responsible for the vast majority of Lewis (a-b-) phenotypes in Caucasians. These mutations are common in the population at large and may be associated with increased risk of coronary heart disease. Further studies using larger samples are warranted.
authors.affiliation: National Public Health Institute, Department of Epidemiology and Health Promotion, Helsinki, Finland. veikko.salomaa@ktl.fi
authors.forename: V
authors.initials: V
authors.lastname: Salomaa
authors.forename: J
authors.initials: J
authors.lastname: Pankow
authors.forename: G
authors.initials: G
authors.lastname: Heiss
authors.forename: B
authors.initials: B
authors.lastname: Cakir
authors.forename: J H
authors.initials: JH
authors.lastname: Eckfeldt
authors.forename: R C
authors.initials: RC
authors.lastname: Ellison
authors.forename: R H
authors.initials: RH
authors.lastname: Myers
authors.forename: K M
authors.initials: KM
authors.lastname: Hiller
authors.forename: K R
authors.initials: KR
authors.lastname: Brantley
authors.forename: T L
authors.initials: TL
authors.lastname: Morris
authors.forename: B W
authors.initials: BW
authors.lastname: Weston
mesh_terms: D001161:Arteriosclerosis / Q000097:blood* / Q000201:enzymology / Q000235:genetics; D003327:Coronary Disease / Q000097:blood* / Q000201:enzymology / Q000235:genetics; D003430:Cross-Sectional Studies; D017931:DNA Primers; D005647:Fucosyltransferases / Q000235:genetics*; D005784:Gene Amplification; D006801:Humans; D007983:Lewis Blood Group Antigens / Q000235:genetics*; D009154:Mutation; D016017:Odds Ratio; D010641:Phenotype
chemical_list: D017931:DNA Primers; D007983:Lewis Blood Group Antigens; D005647:Fucosyltransferases; C019818:3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase